Organic solvents affect the membrane lipids of neurons and glial cell. This led us to search for auditory damage, by means of brainstem auditory evoked responses, in subjects with chronic inhalation of thinner. Waves III and V showed delayed latency at an intensity of 90 dB, and wave V was delayed at 70 and 30 dB; the interwave intervals I-III and I-V at 90 dB and the interpeak I-V at 70 dB were also retarded. Three subjects did not show a response to stimulation at 30 dB: pure tone audiometry showed biaural mild hypoacusia in them. These results show that chronic inhalation of thinner may alter the auditory pathway of addicts.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis.
Biomedicines
January 2025
Department of Medical and Surgical Sciences, University of Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
Asthma is a chronic inflammatory disease with the main anti-inflammatory drugs for better disease control being steroids or corticosteroids. The use of steroids in asthma patients, in particular in uncontrolled asthma patients, is associated with an increased risk of osteoporosis and fragility fractures. A single oral corticosteroid course increases the risk of osteoporosis and the continual use of inhaled corticosteroids is correlated over time to an increased risk for both bone conditions.
View Article and Find Full Text PDFTherapeutic Potential of Herbal Medicines in Combating Particulate Matter (PM)-Induced Health Effects: Insights from Recent Studies.
Antioxidants (Basel)
December 2024
College of Public Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Particulate matter (PM), particularly fine (PM) and ultrafine (PM) particles, originates from both natural and anthropogenic sources, such as biomass burning and vehicle emissions. These particles contain harmful compounds that pose significant health risks. Upon inhalation, ingestion, or dermal contact, PM can penetrate biological systems, inducing oxidative stress, inflammation, and DNA damage, which contribute to a range of health complications.
View Article and Find Full Text PDFCOVID-19-Related Discontinuation Impact on Patient-Reported Outcomes in Long-Term Thermal Therapy: A Single-Center Observational Study at Saturnia Thermal Springs.
Healthcare (Basel)
January 2025
Unit of Prosthodontics, Department of Innovative Technologies in Medicine and Dentistry, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
Background: Thermal therapy represents a well-established therapeutic approach for chronic musculoskeletal and respiratory conditions. To date, no studies have investigated the clinical effects of treatment interruption in thermal medicine. We aimed to evaluate the clinical impact of COVID-19 lockdown-induced thermal therapy discontinuation through validated patient-reported outcomes.
View Article and Find Full Text PDFThe availability of drugs for stable COPD treatment in China: a cross-sectional survey.
NPJ Prim Care Respir Med
January 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
This survey aimed to investigate the availability of drugs for stable chronic obstructive pulmonary disease (COPD) treatment in Chinese hospitals and to determine whether drug availability significantly varied among hospitals with different characteristics. A well-constructed questionnaire was designed according to the Chinese Guidelines for the Diagnosis and Management of COPD (revised version 2021). Both inhaled drugs (monotherapy, double therapy and triple therapy) and oral drugs (expectorants, theophylline, antibiotics, and bacterial lysates) were included in this survey.
View Article and Find Full Text PDFEnsifentrine in COPD patients taking long-acting bronchodilators: A pooled post-hoc analysis of the ENHANCE-1/2 studies.
Chron Respir Dis
January 2025
South Texas Veterans Health Care System, University of Texas Health, San Antonio, TX, USA.
Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis of patients according to background chronic obstructive pulmonary disease (COPD) maintenance medication regimens.
Objective: This analysis aimed to explore the efficacy and safety of ensifentrine in patients receiving long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists with inhaled corticosteroids (LABA + ICS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!